The recent years have witnessed major advances in the treatment of benign rare blood disorders such as hemophilia, sickle cell disease (SCD), and cold agglutinin disease (CAD).
Moreover, new guidelines have been developed for the diagnosis and management of these blood disorders. Clinicians including hematologists and emergency department physicians need to remain up to date on the various aspects of management of these hematological disorders to diagnose, treat, and manage associated complications. Moreover, access to novel therapies remains challenging due to payer restrictions including step therapy policies. Hematologists and their care team need education on streamlining the prior authorization processes to prevent treatment delays.
During this 60-minute recorded symposium, expert panelists will discuss GD, including its less commonly reported manifestations, diagnostic pathways, and patient-centric multidisciplinary management of the disorder.
In this CMEO Snack, join expert faculty as they discuss best strategies to identify risk factors of CMV infection, recognize the impact of CMV on treatment outcomes, and ultimately develop balanced treatment plans for patients with CMV disease.
Expert faculty will assess the common comorbidities and discuss applying anticoagulant strategies that reflect randomized controlled trials (RCTs), real-world data, and individual patient characteristics.
The incidence of, and death from, multiple myeloma (MM) is 50% more in men than in women and over twice among Black people compared with White people, in spite of the fact that Black patients are more likely than White patients to have MM with a favorable risk profile. Much of these disparities in outcomes can be mitigated by providing equitable access to therapy. Among data from 9 previously published clinical trials in patients with newly diagnosed MM, adverse demographic and clinical factors were associated with inferior survival, but race was not. One of the key access points to evidence-based medicine is clinical trials, and unfortunately, non-White patients are underrepresented in clinical trials. As such, greater enrollment of non-White patients into clinical trials needs to be a priority. While there are significant disparities in MM incidence and outcomes among patients of different racial-ethnic groups, clinicians can help reduce this disparity by improving access to evidence-based medicine, including triplet therapies, stem cell transplants, CAR T-cell therapies, and clinical trials.